Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 18/20 | 0.71 |
| ▸ | PDE4A | P27815 | 10/20 | 0.71 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.71 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2587167 | 1.00 | PDE4D (0.71) | PDE4DPDE4APDE4BPDE4CMAPT | |
| SCHEMBL15595474 | 0.92 | PDE4D (0.70) | PDE4DPDE4APDE4BPDE4CMAPT | |
| SCHEMBL15595367 | 0.89 | MAPT (0.57) | PDE4DPDE4APDE4BPDE4CMAPT | |
| SCHEMBL17908087 | 0.88 | PDE4D (0.72) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2586118 | 0.88 | PDE4D (0.72) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2586121 | 0.88 | PDE4D (0.72) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL7362118 | 0.87 | PDE4D (0.55) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL20817359 | 0.86 | PDE4D (0.54) | PDE4DPDE4APDE4BPDE4CMAPT | |
| SCHEMBL3803445 | 0.86 | PDE4D (0.54) | PDE4DPDE4APDE4BPDE4CMAPT | |
| SCHEMBL22688391 | 0.86 | PDE4D (0.54) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021444-B2 | Antiviral compounds | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20140309220-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | disclosed |
| US-20140171427-A1 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-19 | — | — | US | disclosed |
| US-8598164-B2 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2595989-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2013067248-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2011140425-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | PDE4D 1564/4885PDE4A 700/4885PDE4B 636/4885 |
| US-20140171427-A1 | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, TRPV1, KCNJ1 | PDE4D 1017/4885PDE4A 1014/4885PDE4B 1186/4885 |
| US-11021444-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | PDE4D 1564/4885PDE4A 700/4885PDE4B 636/4885 |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | PDE4D 1017/4885PDE4A 1014/4885PDE4B 1186/4885 |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | PDE4D 1564/4885PDE4A 700/4885PDE4B 636/4885 |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | PDE4D 1564/4885PDE4A 700/4885PDE4B 636/4885 |
| US-20140309220-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | KCNJ1, KCNJ2, KCNJ11 | PDE4D 1106/4885PDE4A 751/4885PDE4B 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.